EUVIMEDEUVIMED entdecken
Crossref

2523-P: Early Glycemic Deterioration and Baseline Risk Prediction of Insulin-Like Growth Factor-1 Receptor Inhibitor Therapy

WEI ZHAO, XIUYING ZHANG, JUNJIE DENG, YIHUA XU, SHUJIE LU, LINONG JI

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-2523-p ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von WEI ZHAO und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: Insulin-like growth factor-1 receptor (IGF-1R) inhibitor has been developed as an effective therapy for thyroid eye disease (TED). However, treatment-associated hyperglycemia remains a clinical concern. We aimed to examine whether early glycemic deterioration during IGF-1R inhibitor therapy is associated with subsequent glycemic trajectories and to develop and validate a risk prediction model.

Methods

We analyzed data from three independent randomized clinical trials of the IGF-1R inhibitor IBI311 for TED, including 129 participants treated with IBI311. Two trials served as training cohort (n=76), and the remaining trial served as an independent validation cohort (n=53). Early glycemic deterioration was defined as a ≥0.5% increase in HbA1c by week 6 or initiation/intensification of glucose-lowering therapy within 6 weeks. Associations between early deterioration and glycemic outcomes at treatment completion (24 weeks) were examined in training cohort. A prediction model was developed using baseline metabolic variables with elastic net-regularized logistic regression and externally validated.

Results

Early glycemic deterioration occurred in 18.6% (14/129) of participants. Individuals with early deterioration experienced greater increases in HbA1c (1.13% ± 0.55% vs. 0.17% ± 0.33%; P=0.001) and FBG (1.86 ± 1.79 mmol/L vs. 0.16 ± 0.61 mmol/L; P=0.021) at 24 weeks. At baseline, participants with early deterioration had higher FBG, blood pressure, lower HDL-c, and greater metabolic syndrome (MetS) score. An elastic net model incorporating baseline FBG (standard β=0.25) and MetS score (standard β=0.20) demonstrated good discrimination for early deterioration (external AUC 0.80, 95% CI 0.63-0.94).

Conclusion

Early glycemic deterioration during IGF-1R inhibitor therapy is associated with subsequent hyperglycemia. A simple baseline model using routinely available metabolic measures may enable early risk stratification. Disclosure W. Zhao: None. X. Zhang: None. J. Deng: None. Y. Xu: None. S. Lu: None. L. Ji: None.

Zitieren

APA

ZHAO, W., ZHANG, X., DENG, J., XU, Y., LU, S., & JI, L. (2026). 2523-P: Early Glycemic Deterioration and Baseline Risk Prediction of Insulin-Like Growth Factor-1 Receptor Inhibitor Therapy. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-2523-p

Vancouver

ZHAO W, ZHANG X, DENG J, XU Y, LU S, JI L. 2523-P: Early Glycemic Deterioration and Baseline Risk Prediction of Insulin-Like Growth Factor-1 Receptor Inhibitor Therapy. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-2523-p

BibTeX
@article{ZHAO2026,
  author = {ZHAO, WEI and ZHANG, XIUYING and DENG, JUNJIE and XU, YIHUA and LU, SHUJIE and JI, LINONG},
  title = {2523-P: Early Glycemic Deterioration and Baseline Risk Prediction of Insulin-Like Growth Factor-1 Receptor Inhibitor Therapy},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-2523-p}
}
Kostenlos starten →